Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
  DUBLIN , Sept. 25, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 , at 7:45 a.m. ET . The conference will take place October 2-4 at the
Evidence of Biological Activity in the Lung with Minimal Systemic Exposure Generally Well-Tolerated as a Single Dose in Healthy Volunteers and as a Once-daily Dose for Seven Days in Asthmatics DUBLIN , Sept. 9, 2019 /PRNewswire/ --  Theravance Biopharma, Inc.
DUBLIN , Aug. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 14 th Annual Wells Fargo Securities Healthcare Conference on Wednesday, September 4, 2019 at 1:15 p.m.
- Late-stage clinical studies of TD-1473 and ampreloxetine progressing - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in September 2019 - Strong customer acceptance and brand performance of YUPELRI® (revefenacin) inhalation
DUBLIN , July 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended June 30, 2019 and provide a business update prior to market open on Wednesday, July 31, 2019 .
Durable reductions in OHSA and OHDAS Composite scores reflect improvements in overall symptoms and daily activity throughout 20 weeks of treatment Findings consistent with previously reported reductions in the cardinal symptom of dizziness as measured by OHSA #1 and supportive of ongoing
Durable improvements in neurogenic orthostatic hypotension (nOH) symptom severity sustained over 20 weeks of treatment; symptom severity returns to baseline with treatment discontinuation Data supportive of ongoing registrational Phase 3 program in symptomatic nOH DUBLIN , June 18, 2019
First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a
Experienced Life Science Industry Executive with Strong Track Record of Long-Term Value Creation and Broad Therapeutic Expertise DUBLIN , June 4, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced the appointment of Andrew
Data Demonstrate Signals of Clinical, Histologic and Biomarker Activity Suggesting Localized Target Engagement following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colitis Additional Findings Demonstrate Minimal Systemic Exposure and No Evidence of Systemic